SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (1224)10/16/2002 9:22:38 PM
From: mopgcw  Read Replies (1) of 1784
 
Snipped from an article in Forbes on a new fund manager chris faber. he has had quite a bit of success using a fairly different cashflow model to by stocks:

"One of those, Caliper Technologies, is in the rocket phase. It aims to speed up drug development by making computer chips with microscopic channels that mix chemicals. Big customers include Amgen and Eli Lilly. Though Caliper is still in the red, Faber likes its sales growth, strong patents and $5.22 net cash per share-more than its $4 share price. The market expects a cash flow return in five years of 1%; Faber looks for 6%."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News